Nautilus Biotechnology (NAUT) Liabilities and Shareholders Equity (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $177.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 21.92% year-over-year to $177.8 million; the trailing twelve-month figure through Mar 2026 stood at $783.0 million (down 21.93% YoY), and the FY2025 full-year result was $191.1 million, down 21.27% from the prior year.
• Liabilities and Shareholders Equity retreated to $177.8 million in Q1 2026, from $191.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $384.7 million in Q1 2022 to a low of $177.8 million in Q1 2026.
• A 5-year average of $284.8 million and a median of $288.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 155.6% in 2022 and retreated 22.64% in 2025, its largest moves.
• Tracing NAUT's Liabilities and Shareholders Equity over 5 years: stood at $350.1 million in 2022, then fell by 12.71% to $305.6 million in 2023, then dropped by 20.56% to $242.7 million in 2024, then declined by 21.27% to $191.1 million in 2025, then declined by 6.98% to $177.8 million in 2026.
• Business Quant data shows NAUT's Liabilities and Shareholders Equity at $177.8 million in Q1 2026, $191.1 million in Q4 2025, and $200.9 million in Q3 2025.